<![CDATA[Penelitian ini bertujuan untuk menganalisis Cost of Illness (COI) dan penghematan biaya (cost containment) penggunaan kombinasi antibiotik empirik pasien sepsis dengan sumber infeksi pernapasan di salah satu rumah sakit di Bandung. Penelitian ini menggunakan metode cross sectional dengan pengambilan data secara retrospektif. Data diambil dari rekam medis pasien rawat inap sepsis sumber infeksi pernapasan yang mendapat kombinasi antibiotik empirik seftazidim-levofloksasin dan sefotaksim-eritromisin. Biaya yang dianalisis meliputi biaya langsung dan tidak langsung. Hasil penelitian menunjukkan COI pasien sepsis yang sembuh dengan kombinasi antibiotik empirik seftazidim-levofloksasin sebesar Rp 13.369.055,- sedangkan pada pasien sepsis yang sembuh dengan kombinasi antibiotik empirik sefotaksim-eritromisin sebesar Rp 22.250.495,-. Berdasarkan data tersebut dapat disimpulkan bahwa COI kombinasi antibiotik empirik seftazidim-levofloksasin lebih rendah dibandingkan sefotaksim-eritromisin. Penghematan biaya (cost containment) tanpa mengurangi kualitas pelayanan dapat dilakukan sebesar Rp 8.881.440,- dengan menggunakan kombinasi antibiotik empirik seftazidim-levofloksasin.Kata kunci: Farmakoekonomi, Cost of Illness (COI), penghematan biaya, antibiotik empirik, sepsisCost of Illness and Cost Containment Analysis Using Empirical Antibiotic Therapy in Sepsis Patients in BandungAbstractThe aims of this study were to analyze cost of illness (COI) and cost containment analysis using empiricalantibiotic therapy in sepsis patients with respiratory infection in a hospital in Bandung. A cross sectional method was conducted retrospectively. Data were collected from medical record of inpatients sepsis patients with respiratory infections with empirical antibiotic therapy ceftazidime-levofloxacin or cefotaxime-erythromycin. Direct and indirect cost were calculated and analyzed in this study. The result showed that the average COI for patients with combination ceftazidime-levofloxaxin was 13,369,055IDR whereas combination of cefotaxime-erythromycin was 22,250,495 IDR. In summary, the COI empiricalantibiotic therapy ceftazidime-levofloxacin was lower than cefotaxime-erythromycin. Cost containmentusing empirical antibiotic therapy ceftazidime levofloxacin which without reducing the service quality was 8,881,440 IDR.Key words: Pharmacoeconomic, cost of illness, cost containment, empirical antibiotic, sepsis]]>
